Zacks Research Initiates Coverage on Retension Pharmaceuticals (NASDAQ:RTSN)

Investment analysts at Zacks Research started coverage on shares of Retension Pharmaceuticals (NASDAQ:RTSN) in a research note issued on Wednesday, Zacks reports. The firm set a “hold” rating on the stock.

A number of other research analysts have also weighed in on the company. Leerink Partners assumed coverage on Retension Pharmaceuticals in a research note on Tuesday. They set a “strong-buy” rating on the stock. Guggenheim started coverage on Retension Pharmaceuticals in a research report on Monday. They issued a “buy” rating and a $55.00 price objective for the company. Finally, Oppenheimer assumed coverage on Retension Pharmaceuticals in a research report on Tuesday. They issued an “outperform” rating and a $50.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $52.50.

Retension Pharmaceuticals Trading Down 7.6%

RTSN stock opened at $10.72 on Wednesday. Retension Pharmaceuticals has a one year low of $9.66 and a one year high of $18.64.

Insider Activity

In related news, Director Franklin M. Berger bought 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 13th. The shares were acquired at an average cost of $12.00 per share, with a total value of $120,000.00. Following the completion of the transaction, the director owned 10,000 shares of the company’s stock, valued at approximately $120,000. The trade was a ? increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Eric L. Keller bought 20,800 shares of the stock in a transaction that occurred on Tuesday, October 13th. The stock was bought at an average price of $12.00 per share, with a total value of $249,600.00. Following the completion of the acquisition, the chief executive officer owned 423,377 shares of the company’s stock, valued at $5,080,524. This trade represents a 5.17% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure.

About Retension Pharmaceuticals

We are a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Our product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (“PDE-5”) inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. While first-generation PDE-5 inhibitors, such as Viagra (sildenafil), were originally studied in cardiovascular indications such as hypertension and angina, we believe they did not have adequate bioavailability and tissue penetration to impact the smooth muscle cells of the central vascular and cardiac tissues and thus failed to achieve clinically meaningful reductions in blood pressure.